Glycomics/Glycobiology Market Size, Share, By Product Type (Enzymes, Instruments, Kits & Reagents, and Others), Application (Drug Discovery and Development, Diagnostics, and Others), End-User (Academic and Research Institutes, Pharmaceutical and Biotechno

Glycomics/Glycobiology Market Size, Share, By Product Type (Enzymes, Instruments, Kits & Reagents, and Others), Application (Drug Discovery and Development, Diagnostics, and Others), End-User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, CROs, and Others), and Region - Trends, Analysis, and Forecast till 2035

By 2035, the Glycomics/glycobiology market size is expected to enlarge at USD 10.1 Billion, growing at a CAGR of 15.6%.

Key Highlights:

In July 2018, Agilent Technologies finalized the acquisition of ULTRA Scientific Assets. The company involved in distribution of certified chemical materials and standards. This acquisition was intended to provide life sciences solutions to the company, creating a wider consumer base.

In January 2018, Agilent Technologies Inc. declared that it has formed a strategic scientific collaboration with the University of Southern California (USC) Michelson Center for Convergent Bioscience to produce an Agilent Center of Excellence (CoE) in Biomolecular Characterization.

Key Benefits of Purchasing This Report

• Gain valuable insights into revenue projections for the overall market and its sub-segments, benefiting industry leaders and new entrants.
• Enhance your understanding of the competitive landscape to refine business positioning and optimize go-to-market strategies.
• Stay informed on the latest trends in the Glycomics & Glycobiology Market, including key drivers, challenges, opportunities, and barriers.

Analyst View:

Biotech companies are leading to rise in R&D investments due to growth in their drug discovery and development. Further, increasing the number of initiatives undertaken by the government to upsurge funding for R&D has resulted to the increased need for glycomics techniques. The Australian government invested approximately US$ 10.4 billion for scientific research innovations and activities for the period 2017-2018. In 2015, the Irish Government also invested US$ 5.6 billion spending on research, which was intended to grow the number of scientific research activities from 25,000 to 40,000. Hence, the necessity for glycomics research techniques for leading comprehensive glycomes study is continuously increasing.

Enzymes are projected to estimate for a significant market share over the forecast period due to growing research in cancer therapeutics and diagnosis. Glycomics deals with several research methods to define or quantify glycome of a tissue, cell, or organism. Key players are also undertaking extensive R&D initiatives to develop technologically advanced and new products. For instance, in 2016, ProZyme, Inc. developed Gly-Q Glycan Analysis System, and combined platform that provides high-throughput and user-friendly glycoanalysis.

Key Market Insights from the report:

By 2035, the Glycomics/glycobiology market size is expected to enlarge at USD 10.1 Billion, growing at a CAGR of 15.6%. The market report has been segmented on the basis of product type, application, end-user, and region.

• By product type, the enzymes segment is projected to lead the market in 2020 and is estimated to grow at the highest CAGR in the coming years. The high growth and large share of this segment is mainly due to wide applications pf enzymes and consumable nature and their in a variety of R&D and drug discovery procedures.
• By application, drug discovery & development is the highest and the fastest-growing application segment in the global market, due to growing R&D investments in biotechnology and pharmaceutical companies and the increasing number of drug discovery research activities in academic research institutes.
• By end-user, academic and research institutes estimated for the highest revenue share in 2018 owing to increased R&D investments. Collaborations between research institutes and major organizations are further propelling the segment expansion.
• By region, North America estimated for the highest market share in 2018 owing to the presence of major pharmaceutical and biopharmaceutical companies including Agilent Technologies, Merck KGaA, Danaher, and Thermo Fisher Scientific.

Segmentation:

By Product Type:

• Enzymes
• Glycosidases
• Transferases
• Instruments
• Mass Spectrometry
• Chromatography
• Arrays
• Kits
• Reagents
• Others

By Application:

• Drug Discovery and Development
• Diagnostics
• Others

By End User:

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• CROs
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• Indonesia
• Malaysia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• GCC
• Israel
• South Africa
• Rest of Middle East & Africa

Glycomics Glycobiology Market Competitive Landscape

• Thermo Fisher Scientific Inc.
• New England Biolabs
• Promega Corporation
• Merck KGaA
• Waters Corporation
• Takara Bio Inc.
• Bio-Techne
• Agilent Technologies, Inc.
• Sumitomo Bakelite Co., Ltd.
• Bruker
• Pegasus Laboratories, Inc.
• Shimadzu Corporation
• Danaher
• RayBiotech, Inc.

Key Questions Answered in This Report

1. What was the size of the Glycomics & Glycobiology Market in 2024?

2. What is the expected growth rate of the Glycomics & Glycobiology Market during 2025-2035?

3. What are the key factors driving the Glycomics & Glycobiology Market?

4. What is the breakup of the Glycomics & Glycobiology Market based on the distribution channel?

5. What are the key regions in the Glycomics & Glycobiology Market?

6. Who are the key players/companies in the Glycomics & Glycobiology Market?

7. What are the drivers, restraints, and opportunities in the Glycomics & Glycobiology Market?